

RESEARCH OPPORTUNITY

NAMI is committed to ensuring that the most effective treatments for mental illness are available to those who need them. Determining which treatments are most effective requires research. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously. NAMI's Chief Medical Officer Dr. Ken Duckworth and Chief Program Officer Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved by an Institutional Review Board (IRB) to assure the safety of those involved.

NAMI does not accept financial compensation for recruiting clinical trial participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these trials.

If you have questions about research at NAMI, please visit [NAMI.org/research](https://www.nami.org/research) or email us at research@nami.org.

WHAT IS THE STUDY?

This study is a clinical research trial for a medication to treat depression in people who have been diagnosed with bipolar I disorder. The trial will determine if this investigational medication is safe and effective in patients with major depressive episodes associated with bipolar I disorder who have not responded to other forms of treatment or have experienced adverse side effects with other treatments. Participants will be randomly assigned to one of three groups to receive different doses of the medication or a placebo for a period of six weeks. Including the screening process and follow-up process, the study could last for up to 10 weeks (2.5 months). Reimbursement may be available for travel and associated costs throughout the duration of the study.

WHO CAN PARTICIPATE?

This study is seeking 100 participants from the United States and 522 total participants across the United States, Japan, Europe, and Latin America.

Individuals may be eligible for this study if they are:

- Between the ages of 18 and 65
- Diagnosed with bipolar I disorder
- Currently feeling depressed

Please note that these criteria are not complete. Certain factors, including other mental health diagnoses, may disqualify an individual from participation. Please visit this site for more information:
<https://clinicaltrials.gov/ct2/show/NCT05169710#eligibility>

WHERE IS THE STUDY TAKING PLACE?

For more details about the study location(s), please visit this site:
<https://clinicaltrials.gov/ct2/show/NCT05169710#contactlocation>

HOW DO I LEARN MORE?

If you have questions or would like more information, please visit the study website:
<https://www.releasebipolardepressionstudy.com/>